NEW YORK, May 29, 2026, 15:05 EDT
- Orchestra BioMed traded 0.8% lower at $3.95 Friday afternoon, lagging the SPDR S&P Biotech ETF’s 0.4% gain.
- Orchestra BioMed aims to finish enrolling patients in its BACKBEAT pivotal trial by the close of the third quarter of 2026.
- Management will take part in the Jefferies Global Healthcare Conference on June 4.
Orchestra BioMed Holdings shares fell in Friday afternoon trade. Investors seemed to look ahead to upcoming milestones for its Medtronic-partnered hypertension therapy, while the news flow stayed quiet.
The stock traded lower, falling 0.8% to $3.95 as roughly 116,000 shares changed hands. The move trailed the broader biotech sector, where the SPDR S&P Biotech ETF added 0.4%, but the iShares Nasdaq Biotechnology ETF slipped 0.2%.
Orchestra BioMed barely moved, but that’s still key since the company isn’t a revenue story yet. Its main focus is on the AVIM Therapy, now in BACKBEAT — a late-stage trial aimed at regulatory approval. The trial is for patients with uncontrolled hypertension who have, or just got, a dual-chamber pacemaker.
Orchestra BioMed said this month it expects to wrap up BACKBEAT trial enrollment by the end of the third quarter. The company and Medtronic are targeting a late-breaking data presentation at a major cardiovascular conference in the second quarter of 2027. Medtronic will go for an FDA marketing application after the data, provided the trial’s primary safety and efficacy endpoints are met, according to the company.
Orchestra BioMed chairman and CEO David Hochman said the company made “meaningful advancements” during the first quarter in its late-stage cardiovascular pipeline. Hochman mentioned “value inflection points” ahead, a phrase that usually means trial, regulatory or financing news for investors in development-stage medical-device names. GlobeNewswire
Medtronic is still a key piece of the stock story. Robert C. Kowal, vice president and general manager for cardiac pacing therapies at Medtronic’s Cardiac Rhythm Management unit, said the BACKBEAT trial is looking at whether AVIM can “extend the benefits of pacing” to hypertension management. GlobeNewswire
Orchestra BioMed is set for a couple investor events. Hochman is scheduled to take part in a fireside chat with Jefferies Managing Director Matt Taylor at 9:55 a.m. ET on June 4. The company will also set up one-on-one investor meetings on June 3 and June 4.
Orchestra BioMed finished March with $94.4 million in cash, cash equivalents and marketable securities. On May 1, the company got another $35 million from Medtronic and Ligand, as laid out in past agreements. Management said the current cash should last into the fourth quarter of 2027.
Orchestra BioMed’s expenses moved higher. Net loss for the first quarter attributable to common stockholders widened to $20.7 million, or 33 cents per share, compared with $18.8 million, or 49 cents a share, a year ago. Revenue came in at $0.1 million, down from $0.9 million. R&D spending jumped 17% to $15.8 million, driven mostly by progress on BACKBEAT and the Virtue SAB program.
Competition is real in device-based hypertension. Medtronic’s Symplicity Spyral and Recor Medical’s Paradise devices cleared the FDA in 2023; both use renal denervation, a catheter technique that interrupts kidney nerve signals linked to high blood pressure. Orchestra’s AVIM isn’t the same—it’s a pacemaker-driven approach and has a smaller target, focusing on patients who already need pacing.
FDA Breakthrough Device Designation is the regulatory tag investors focus on. It’s designed to accelerate review of certain devices targeting serious or life-threatening conditions. Orchestra BioMed said its AVIM device holds two of these designations for uncontrolled hypertension patients, including those needing pacemakers.
The downside is clear. In its SEC filing, the company pointed to its limited operating history, an accumulated deficit that stood at $383.3 million as of March 31, and projected significant operating losses ahead. It also will need more capital to bring its products closer to commercialization. Trial timelines can slip, data could disappoint, and a better balance sheet doesn’t take away clinical risk.
The stock is now trading more on a few specific dates than on normal sales patterns: Jefferies’ event coming up next week, the timeline for completing BACKBEAT enrollment later this year, and a scheduled data readout in 2027. The market is just waiting for the next move.
